- Home
- IMRN vs INDP Comparison
IMRN vs INDP Comparison
Compare IMRN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- INDP
- Stock Information
- Founded
- IMRN 1994
- INDP 2000
- Country
- IMRN Australia
- INDP United States
- Employees
- IMRN N/A
- INDP N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- INDP Health Care
- Exchange
- IMRN Nasdaq
- INDP Nasdaq
- Market Cap
- IMRN 15.0M
- INDP 15.4M
- IPO Year
- IMRN N/A
- INDP N/A
- Fundamental
- Price
- IMRN $2.69
- INDP $1.16
- Analyst Decision
- IMRN Strong Buy
- INDP Strong Buy
- Analyst Count
- IMRN 1
- INDP 1
- Target Price
- IMRN $5.00
- INDP $12.00
- AVG Volume (30 Days)
- IMRN 5.6K
- INDP 22.5K
- Earning Date
- IMRN 10-15-2024
- INDP 11-04-2024
- Dividend Yield
- IMRN N/A
- INDP N/A
- EPS Growth
- IMRN N/A
- INDP N/A
- EPS
- IMRN N/A
- INDP N/A
- Revenue
- IMRN $3,271,194.00
- INDP N/A
- Revenue This Year
- IMRN N/A
- INDP N/A
- Revenue Next Year
- IMRN N/A
- INDP N/A
- P/E Ratio
- IMRN N/A
- INDP N/A
- Revenue Growth
- IMRN 171.67
- INDP N/A
- 52 Week Low
- IMRN $1.48
- INDP $1.03
- 52 Week High
- IMRN $5.96
- INDP $3.25
- Technical
- Relative Strength Index (RSI)
- IMRN 51.76
- INDP 36.05
- Support Level
- IMRN $2.66
- INDP $1.11
- Resistance Level
- IMRN $2.87
- INDP $1.27
- Average True Range (ATR)
- IMRN 0.11
- INDP 0.13
- MACD
- IMRN 0.00
- INDP -0.00
- Stochastic Oscillator
- IMRN 54.85
- INDP 22.03
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.